Blenrep

Active Ingredient(s): Belantamab Mafodotin-blmf
FDA Approved: * August 5, 2020
Pharm Company: * GLAXOSMITHKLINE
Category: Cancer

Belantamab mafodotin, sold under the brand name Blenrep, is a medication for the treatment of relapsed and refractory multiple myeloma.[1][3][4][2] The most common adverse reactions include keratopathy (corneal epithelium change on eye exam), decreased visual acuity, nausea, blurred vision, pyrexia, infusion-related reactions, and fatigue.[1][3] Belantamab mafodotin is a humanized IgG1κ monocl... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Blenrep 50 mg/ml Intravenous Injection, Powder, Lyophilized, for Solution

NDC: 0173-0896

Labeler:

Glaxosmithkline LLC